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Abstract
Background: Tacrolimus is available as twice-daily Prograf® (Tac-BID) and the once-daily formulation, Advagraf®
(Tac-OD). Although therapeutically equivalent, some transplant recipients require dose adjustments to achieve
similar tacrolimus trough concentrations [Tac C0] after conversion between formulations. Tacrolimus is primarily
metabolized by cytochrome P450 3A5 (CYP3A5). We sought to determine whether genetic polymorphisms in the
CYP3A5 enzyme; CYP3A5 *1/*1 and CYP3A5 *1/*3 (expressers) compared to CYP3A5 *3/*3 (non-expressers) could
account for discrepancies in dose requirements following conversion from Tac-BID to Tac-OD.
Methods: A cohort of 60 renal transplant recipients (RTR) from our larger conversion study of 496 patients underwent
additional testing for CY3A5 genetic polymorphisms. Analysis included demographics, tac dosing and [Tac C0] pre- and
post-conversion and dosing changes relative to CYP3A5 genotypes. CYP3A5 genetic polymorphisms were identified
through analysis of genomic DNA.
Results: Conversion from tac bid to tac OD in this cohort required a mean (SD) dose increase from 3.1 (1.0) mg/day to
3.8 (1.3) mg/day (p = 0.007), to achieve similar [Tac C0]. The *1/*3 expresser group required a greater percentage dose
adjustment (56.7 %) in converting from Tac-BID to Tac-OD as compared to the *3/*3 non-expresser group (26.6 %). Similar
findings were observed with the both expresser groups combined (*1/*1 &*1/*3). The expressers were significantly more
highly represented in the East Asian cohort.
Conclusions: The CYP3A5 expresser polymorphism necessitates an increase in dosing upon conversion from Tac-BID
to Tac-OD, with the expresser genotypes contributing significantly to this finding. Given the variability in frequency of
CYP3A5 genotypes in various ethnic groups, future studies should account for both isoenzyme polymorphism and
ethnicity in optimizing dosing requirements.
Trial registration: Clinical trials.gov identifier: NCT01884480
* Correspondence: zaltzmanj@smh.ca
3Division of Nephology and Transplant, Department of Medicine, St.
Michael’s Hospital, Li-Ka Shing Knowledge Institute, University of Toronto,
Toronto, Canada
Full list of author information is available at the end of the article
© 2016 Zaltzman et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zaltzman et al. Transplantation Research  (2016) 5:2 
DOI 10.1186/s13737-016-0031-6
Introduction
The calcineurin inhibitor tacrolimus is the most widely
used immunosuppressive agent for the prevention of re-
jection following kidney transplantation. The branded
agent is commercially available in two oral formulations,
twice-daily Prograf® (Tac-BID) and once-daily Advagraf®
or Astagraf® in the US (Tac-OD). Previous studies have
shown the two formulations to be therapeutically
equivalent [1, 2]. However, there is mounting evidence
that a 1:1 conversion does not result in bioequivalence
for all patients, with conversion from the BID to the OD
formulation often resulting in under exposure as defined
by tacrolimus trough concentration [Tac C0] [3–5].
Our previous work demonstrated that differences in
ethnicity play a role in dose adjustment requirements
when switching from Tac-BID to Tac-OD. In our Con-
version Study of 496 renal transplant recipients (RTR) in
a single centre converted from Tac-BID to OD, we found
that 27.5 % of East Asians versus 13.5 % of Caucasians
required a dose increase of 30 % or greater when switch-
ing from BID to OD [6].
CYP3A5 has been identified as the major intestinal
and hepatic enzyme responsible for Tac metabolism [7].
Variability in its pharmacokinetics has been explained
by a single nucleotide polymorphism. The CYP3A5 ac-
tivity is largely determined by the single nucleotide
variant (SNV) CYP3A5*3 (6986A > G; rs776746), which
results in alternate mRNA splicing and a truncated and
non-functional protein [8]. In homozygous carriers
CYP3A5*3/*3 (non-expressers), the result is the absence
of protein activity compared to the CYP3A5*1/*1 and
CYP3A5*1/*3 (expressers) [9–11]. Non-expressers are
believed to have a higher bioavailability and exposure
of Tac, in part because of increased intestinal absorp-
tion and thus require lower doses to achieve target
concentration compared to expressers [12].
Given that 20–30 % of patients may require some dose
increase upon conversion from Tac-BID to Tac-OD to
maintain similar trough tacrolimus concentrations [5, 6],
we sought to explore whether genetic polymorphisms in
the CYP3A5 enzyme, in particular the CYP3A5*1/*1 and
CYP3A5*1/*3 (expressers) compared to CYP3A5*3/*3
(non-expressers) could account for discrepancies in dose
requirements following conversion from Tac-BID to
Tac-OD.
Materials and methods
As reported in our Conversion Study, 496 stable RTRs
receiving Tac-BID were converted to Tac-OD [6]. In the
large conversion trial, we examined dosing increases and
decreases in the entire cohort required to maintain
steady state [Tac C0] at 12 months post-conversion.
The current study involved recruitment of a cohort of
60 participants from the initial cohort of 496 with an
aim to recruit recipients with a range of tac dosing re-
quirements following conversion. We attempted to
match based on age, transplant duration, renal function
and transplant source. All [Tac C0] were done at our in-
stitution using high performance liquid chromatography
mass spectrometer (HPLC-MS; Shimadzu Scientific
Tokyo, Japan). Tacrolimus assay performance was char-
acterized by six standardization references on a twice-
daily basis. Genomic DNA obtained from whole blood
using the MagNA Pure Compact Nucleic Acid Isolation
Kit I (Roche Diagnostics, Laval, Quebec, Canada) was
used to identify the variants of the cytochrome P450 en-
zyme CYP3A5 (CYP3A5*3*3, CYP3A5*1*3, CYP3A5*1*1).
The CYP3A5*3 (g.6986A >G, rs776746) TaqMan allelic dis-
crimination assay (Life Technologies, Burlington, Ontario,
Canada) was used for genotyping. Hardy–Weinburg equi-
librium was assessed for genotypes using the χ2 goodness-
of-fit test. SAS® software version 9.2 (Cary, NC, USA) was
used for all analyses. Comparisons of tac dosing changes
were done by paired t test and ANOVA for multiple
comparisons. Chi-square analysis and Fisher’s exact tests
were used for tac dose changes by genotype and genotyp-
ing by ethnicity. All participants provided written consent
and the Research Ethics Board at St. Michael’s Hospital ap-
proved the study.
Results
Demographics of the study cohort are shown in Table 1.
The study population was 46.7 % females, with 53 %
having received living donor kidneys. The majority of re-
cipients were Caucasian (53 %), 26.7 % were of East Asian
origin and 8.3 % of South Asian descent. Recipients had
Table 1 Demographics of transplant cohort
Variable N = 60
Female (%) 28 (46.7)
Deceased donor (%) 32 (53.3)
Ethnicity (%)
-Caucasian 34 (57)
-East Asian 16 (26.7)
-South Asian 5 (8.3)
-Black 2 (3.3)
-Other 3 (5.0)
Age at conversion 53.9 ± 9.5
Years post-transplant 7.4 ± 3.8
eGFR at conversion (ml/min) 62 ± 36.2
Tac BID dose pre-conversion (mg/day) 3.1 ± 1.0
Tac OD dose 12 months post-conversion (mg/day) 3.8 ± 1.3*
[Tac C0 BID] pre-conversion (ng/ml) 5.2 ± 1.6
[Tac CO OD] post-conversion (ng/ml) 5.1 ± 1.5
BID twice daily, OD once daily, Tac tacrolimus
*p = 0.007 for Tac dose BID versus OD
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been transplanted for a mean of 7.4 years prior to con-
version, with an eGFR of 62 ml/min. As demonstrated
in Fig. 1, upon conversion from Tac-BID to Tac-OD,
tac dosing increased from 3.1 ± 1.0 mg/day to 3.8 ±
1.3 mg/day to maintain similar [tacC0] at 12 months
post-conversion (p = 0.007). The mean haemoglobin
was 132 ± 34 g/l. Fifteen patients were on diltiazem;
however, there is no change in dose or frequency of use
pre- or post-conversion.
Genotypes
Of the cohort of 60, 43 (71.6 %) recipients were CYP3A5
*3/*3 (non-expressers), while 13 (21.7 %) were *1/*3 and 4
(6.7 %) *1/*1 (heterozygote and homozygote expressers,
respectively).
BID dosing (pre-conversion)
As shown in Fig. 2, in comparing CYP3A5 genotype
groups, the *1/*1 expressers required the highest Tac-BID
doses (6.3 ± 3.3), followed by the *1/*3 expressers (4.1 ±
2.4) and the *3/*3 non-expressers (2.4 ± 1.2). However, the
*1/*1 group had a limited sample size of n = 4, and thus,
no significant differences were shown with this group
compared to the *1/*3 and *3/*3. There was a significant
dose difference between the *1/*3 and *3/*3, p = 0.003.
OD-dosing (12 months post-conversion)
Sixty-nine percent of the *1/*1 and *1/*3 (expressers)
and 47 % of the *3/*3 (non-expressers) required some
increase in dose following conversion (p = 0.004). The
mean dose increase for the blended expresser cohort
was 45.3 % (±48) versus 26.6 % (±32.1) for the non-
expressers, p = 0.003. These results are highlighted in
Table 2. As shown in Fig. 3, significant differences in
dose increases following conversion were found for the
*1/*3 (56.7 %) as compared to the *3/*3 (26.6 %). The
mean dose increase for the four patients who expressed
the *1/*1 genotype was 8.3 %.
Ethnicity and genotype
As shown in Table 3, 8 recipients of 16 (50 %) of the
East Asian cohort had CYP3A5 expresser genotypes.
This was significantly higher than the Caucasian cohort
alone (p = 0.011). Of the East Asian cohort who were ex-
pressers, the mean dose increase following conversion
was 53 % compared to 35 % increase for non-expressers.
Owing to the small sample size, this result was not
statistically significant.
Discussion
Initially, the recommended conversion from Tac-BID to
Tac-OD was 1 mg:1 mg, as these were considered thera-
peutically equivalent [1, 2]. However, further experience
has shown that tacrolimus exposure is reduced in some
RTRs following conversion [3, 5, 6, 11]. The multicentre
European conversion study of 1832 RTRs mandated an
increase ratio of 1 mg of Tac BID to 1.1 mg of Tac OD
in participants with [Tac C0] < 6 ng/ml [13]. In our cohort
of 60, a mean tac increase of 18 % post-conversion was
required to achieve steady state [Tac C0] by 12 months.
Our study suggests that dose increase upon conversion
may be directly related to differences in CYP3A5 polymor-
phisms. In particular, the highest increase in Tac dose fol-
lowing conversion was seen in CYP3A5 expressers. In
comparing the genotypes, the *1/*1 expressers required
the highest Tac-BID and Tac-OD doses, followed by the
*1/*3 expressers and the *3/*3 non-expressers. This is con-
sistent with previous research on both adult and paediatric
populations, reporting that expressers require higher
doses of tacrolimus, due to higher oral clearance [14, 15].
It was demonstrated that the *1/*3 expressers and the
combined *1/*3 and *1/*1 expressers required signifi-
cantly higher doses of Tac-OD after conversion from
Tac-BID. The increase in dose requirement upon con-
version was attributed primarily to the *1/*3 expresser
cohort because while the homozygous*1/*1 represents
the greatest “expression”, this cohort was a relatively
small sample (only 4/60) and therefore underpowered as
a single group to contribute meaningfully to the data.
Similar findings were demonstrated by Glowacki et al.
who showed that RTRs with the expresser genotype
required a dose increase upon conversion compared to
no increase in non-expresser recipients [16].
There are inconsistent reports on expresser pheno-
types and Tac-OD, with Niioka demonstrating reduced
Tac exposure in *1/*1 and *3/*3 recipients [17]. Some
groups have found opposing effects of CYP3A5 polymor-
phisms on the pharmacokinetics of Tac-OD, with *3/*3
patients demonstrating significantly lower tacrolimus
concentration and area under the curve after conversion,
with no change in levels for the *1/*1 patients [18].
These results have been compatible with previous re-



































Fig. 1 Tacrolimus dosing (mg/day) and mean tacrolimus trough
concentration (ng/ml) pre- and post-conversion
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paediatric studies had relatively small sample sizes, with
unequal or unclear distribution of CYP3A5 polymor-
phisms, thereby making comparisons to the current
study more difficult. Additionally, body weight has a sig-
nificant impact on the pharmacokinetics of tacrolimus in
the paediatric population, which was not accounted for
in the current adult study.
Genetic polymorphisms influence the pharmacokinetic
variability between individuals. Oral clearance of tacrolimus
is higher in CYP3A5*1 expressers (lower dose-adjusted
[C0]), as these individuals have the isoenzyme enhancing
drug metabolism [10, 20]. Therefore, CYP3A5*3 patients
have greater bioavailability of tacrolimus and require lower
doses to achieve target blood levels [9, 10]. Niioka et al. re-
ported that tacrolimus bioavailability was associated with
both the CYP3A5 polymorphism and the oral formulation
(BID versus OD). Bioavailability was lowest in recipients
with the CYP3A5*1 allele taking Tac-OD. The Tac-OD
formulation is released more slowly, and thus absorbed,
further along the GI tract and thus has longer gut exposure
time than the Tac-BID formulation [17]. Since CYP3A5 is a
resident throughout the small intestine, greater exposure in
expressers (*1/*1 &*1/*3) can result in even more
metabolism of tacrolimus to its inactive metabolite des-
methyl FK-506 [21] compared to *3/*3 non-expressers. A
difference in CYP3A5 protein expression level in the small
intestine may influence the oral bioavailability of tacrolimus
in both initial exposure to Tac and in steady state. There-
fore, CYP3A5 expression has a greater influence on the
pharmacokinetics of Tac-OD than Tac-BID.
In our larger study of 496 recipients converted from
Tac-BID to Tac-OD, it was found that 16 % of RTRs re-
quired a dose increase of at least 30 % upon conversion
to Tac-OD. Of these individuals, dose increases were re-
quired most frequently in the East Asian cohort [6].
CYP3A5*1/*1 and *1/*3 genotypes are believed to be
more prevalent in East Asians, as compared to other
ethnic groups such as Caucasians [22]. This current
work further validates the data from our larger conver-
sion trial. The 16 East Asian recipients had a 50 %
“expresser genotype” which was statistically different
from both the largest cohort of 34 Caucasians. Previous
research examining the East Asian patient population
has reported similar findings that CYP3A5 expressers re-
quire higher doses of Tac-OD than Tac-BID. Niioka
et al. reported 25 % lower area-under-the-curve values
upon conversion to Tac-OD in Japanese RTRs [17]. Fur-
thermore, this was primarily in those participants with
the CYP3A5*1/*3 genotype. Additionally, Zhang et al.
found that Chinese CYP3A5*1/*3 expressers required
significant dose increases upon conversion in order to
maintain therapeutic tacrolimus blood levels as com-
pared to CYP3A5*3/*3 non-expressers [23]. The results
of the present study confirm these findings, suggesting
that CYP3A5 genotype contributes significantly to tacro-
limus requirements upon conversion, more specifically
in the CYP3A5*1/*3 subtype. In the current study, the
cohort size of Black patients was too small to examine























Fig. 2 Tacrolimus dosing (mg/day) pre-conversion (Tac-BID) by genotype
Table 2 Tacrolimus dosing pre- and 12 months post-conversion
comparison by genotype: expressers (*1/*1 + *1/*3) and
non-expressers (*3/*3)
Variable *1/*1 and *1/*3 *3/*3 p value
N = 17 N = 43
Required Tac dose increase (%) 10 (59) 20 (47) 0.004
Tac BID (mg/day) 4.6 ± 2.7 2.4 ± 1.2 0.0003
Tac OD (mg/day) 6 ± 2.7 2.9 ± 1.2 0.0001
Tac dose adjustment from
BID to OD (%)
45.3 ± 48.3 26.6 ± 32.1 0.003
BID twice daily, OD once daily, Tac tacrolimus
*1/*3 expressers; *3/*3 non-expressers
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hypothesized that the higher dose requirements upon
conversion in the CYP3A5 expresser cohorts (*1/*1 and
*1/*3) might occur with the greatest frequency in the
East Asian population. However, ethnicity alone may not
be predictive of dose increase. As evidenced by results
from our larger study and others [24], the African
American cohort required the highest doses of Tac both
pre- and post-conversion. However, the required in-
crease post-conversion was <1 % of the pre-conversion
dose [6].
The small sample size of the *1/*1 was a limitation of
our study. However, the homozygous expresser group
in general is underrepresented in the renal transplant
population. In addition, this study did not address
other proteins involved in tacrolimus metabolism such
as P-glycoprotein or CYP3A4 [25, 26].
Conclusions
The present study confirms that conversion from Tac-BID
to Tac-OD necessitates an increase in dosage for RTRs
with CYP3A5 expresser polymorphism. The magnitude of
this increase can be attributed to the heterozygous ex-
presser genotype (*1/*3), and likely the homozygous *1/*1.
Ideally, genetic polymorphism testing prior to tacrolimus
dosing may help to achieve the target tacrolimus blood
levels post-transplant. However, given that there appears
to be a variation in the proportion of expresser genotypes
between ethnic groups, ideal clinical application should
account for both ethnicity and CYP3A5 polymorphisms to
optimize initial tacrolimus dosing and conversion
strategies.
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